- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04207346
Transcranial Magnetic Stimulation to Improve Functioning in Veterans With PTSD (rTMS for PTSD)
Study Overview
Detailed Description
Background Posttraumatic Stress Disorder (PTSD) is an often chronic and disabling condition prevalent in the Veteran population. While there is sufficient evidence to demonstrate the effectiveness of medications and psychotherapy for improving PTSD symptoms, there has been limited study of functioning as an outcome, and the role of other treatments such as somatic therapies. One promising but understudied somatic treatment for PTSD is repetitive transcranial magnetic stimulation (TMS). The characteristics of TMS treatment are different than those of existing treatments and may provide alternative treatment to Veterans who do not respond to medications and psychotherapy. Further, it is possible that TMS may have a greater effect on functioning and lead to higher rates of recovery compared with medications or psychotherapy.
Objective To determine whether Veteran participants with PTSD who receive TMS delivered to the right dorsolateral prefrontal cortex at 1 Hz have greater improvements in: PTSD symptoms, functioning, and depressive symptoms than Veterans receiving sham treatments at treatment completion and at 3 and 6 months after treatment completion.
Method 91 Veterans with PTSD will be randomly assigned to receive low frequency TMS or sham TMS. All TMS will be applied to the right dorsolateral prefrontal cortex. PTSD symptoms, functional outcomes, and depressive symptoms will be measured for all participants at treatment completion, 3 months, and 6 months after completion.
Hypothesis Veterans with PTSD receiving TMS will have greater improvements in PTSD symptoms, functioning, and depressive symptoms at treatment completion and at three and six months after treatment completion compared to Veterans receiving sham TMS.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Bradley V Watts, MD MPH
- Phone Number: 5235 (802) 295-9363
- Email: Bradley.Watts@va.gov
Study Locations
-
-
Vermont
-
White River Junction, Vermont, United States, 05001-3833
- Recruiting
- White River Junction VA Medical Center, White River Junction, VT
-
Contact:
- Cory E Gaudette, AA
- Phone Number: 6880 (802) 295-9363
- Email: cory.gaudette@va.gov
-
Principal Investigator:
- Bradley V Watts, MD MPH
-
Contact:
- Diane L Rivera
- Phone Number: 802-369-0780
- Email: Diana.Rivera@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 19 and 70
- Moderate to severe PTSD as determined by the CAPS within 7 days of randomization.
- Agree to have CAPS audio-recorded.
- Ability to obtain a Motor Threshold using the TMS device during screening.
- Patient eligible for VA healthcare.
- If female with childbearing potential, use of acceptable method of birth control (i.e., use of contraceptives, abstinence).
- Able to read, understand, and sign the informed consent document.
Exclusion Criteria:
- Pregnant or lactating woman.
- Current use of clozapine (any dose) or bupropion (more than 300mg per day).
- Cardiac pacemaker or implantable defibrillator.
- Presence of any metal object in the head, including cochlear implants, but excluding dental work in the mouth.
- Significant central nervous system disorder (stroke, brain mass, epilepsy).
- Seizure in past one year.
- Current psychosis or mania.
- Prior use of TMS.
- Significant suicidal ideation.
- Unstable medical conditions.
- Current alcohol or substance use disorder (except nicotine) that interferes with the patient's ability to participate.
- CPT or PE for PTSD in the past 2 months.
- Changes in Fluoxetine, Paroxetine, Sertraline, or Venlafaxine in the past 2 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TMS
transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex at 1 Hz
|
High-performance magnetic stimulator designed for clinical use or use in clinical trials.
This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment.
The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient.
This arm will use the active side.
Other Names:
|
Sham Comparator: Sham
sham transcranial magnetic stimulation delivered to the right dorsolateral prefrontal cortex
|
High-performance magnetic stimulator designed for clinical use or use in clinical trials.
This specific device has a coil designed with one side that delivers active treatment and the other side that delivers sham (no stimulation) treatment.
The sham side is externally identical to the active side, but internally it has a shield that prevents any magnetic energy from interacting with the patient.
This arm will use the sham side.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CAPS
Time Frame: Baseline
|
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD.
The score ranges from 0-80 with a higher score indicating worse symptoms.
It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
|
Baseline
|
WHODAS
Time Frame: Baseline
|
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society.
The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials.
The total score ranges from 0-100 with a higher score indicating worse functioning.
|
Baseline
|
QIDS SR-16
Time Frame: Baseline
|
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression.
The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV.
The score ranges from 0-27 with a higher score indicating worse depression.
|
Baseline
|
CAPS
Time Frame: 2 weeks
|
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD.
The score ranges from 0-80 with a higher score indicating worse symptoms.
It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
|
2 weeks
|
CAPS
Time Frame: 3 months
|
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD.
The score ranges from 0-80 with a higher score indicating worse symptoms.
It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
|
3 months
|
CAPS
Time Frame: 6 months
|
The Clinician-administered scale of PTSD symptoms (CAPS) queries the frequency and intensity of symptoms of PTSD.
The score ranges from 0-80 with a higher score indicating worse symptoms.
It is considered the gold standard for diagnosis and symptoms assessment in PTSD clinical studies.
|
6 months
|
WHODAS
Time Frame: 2 weeks
|
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society.
The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials.
The total score ranges from 0-100 with a higher score indicating worse functioning.
|
2 weeks
|
WHODAS
Time Frame: 3 months
|
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society.
The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials.
The total score ranges from 0-100 with a higher score indicating worse functioning.
|
3 months
|
WHODAS
Time Frame: 6 months
|
The World Health Organization Disability Assessment Schedule 2.0 (WHODAS) is a 36 item self-report instrument that assesses disability and function across six domains: communicating, getting around, self-care, getting along with people, life activities, and participation in society.
The WHODAS has been used as an outcome of function and disability across many disorders and is commonly used in mental health treatment trials.
The total score ranges from 0-100 with a higher score indicating worse functioning.
|
6 months
|
QIDS SR-16
Time Frame: 2 weeks
|
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression.
The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV.
The score ranges from 0-27 with a higher score indicating worse depression.
|
2 weeks
|
QIDS SR-16
Time Frame: 3 months
|
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression.
The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV.
The score ranges from 0-27 with a higher score indicating worse depression.
|
3 months
|
QIDS SR-16
Time Frame: 6 months
|
The Quick Inventory of Depressive Symptomatology (QIDS SR-16) is a 16-item self-report measure of depression.
The QIDS SR-16 includes nine domains that relate to the nine primary symptoms of major depressive disorder in the DSM-IV.
The score ranges from 0-27 with a higher score indicating worse depression.
|
6 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Bradley V Watts, MD MPH, White River Junction VA Medical Center, White River Junction, VT
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- D2905-R
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
University of Alabama, TuscaloosaRecruiting
-
Research Foundation for Mental Hygiene, Inc.University of California, San Diego; Northwell Health; Columbia University; Icahn... and other collaboratorsRecruiting
-
University of Wisconsin, MadisonWisconsin Partnership ProgramRecruiting
-
Rush University Medical CenterRecruiting
-
New York State Psychiatric InstituteCompleted
-
University of WashingtonPatient-Centered Outcomes Research Institute; Boston University; Washington State... and other collaboratorsActive, not recruiting
-
VA Salt Lake City Health Care SystemUtah State UniversityActive, not recruiting
-
VA Office of Research and DevelopmentCompleted
Clinical Trials on TMS 1 hz
-
Instituto Nacional de Psiquiatría Dr. Ramón de...Universidad Nacional Autonoma de MexicoCompleted
-
University Hospital TuebingenCompleted
-
Rutgers, The State University of New JerseyRecruiting
-
National Institute of Neurological Disorders and...CompletedParkinson DiseaseUnited States
-
Rutgers, The State University of New JerseyRecruitingSpatial NavigationUnited States
-
Seton Healthcare FamilyAbbott Medical Devices; University of Texas at AustinTerminated
-
University of MinnesotaCompletedNon-invasive Neuromodulation in Healthy SubjectsUnited States
-
Douglas Mental Health University InstituteCompletedBipolar DepressionCanada
-
EyeGene Inc.Novotech (Australia) Pty LimitedCompletedPrevention of Herpes Zoster (HZ)Australia
-
United States Naval Medical Center, San DiegoTerminatedPTSD - Post Traumatic Stress Disorder